Lipoxin A4-d5

Lipoxin A4-d5 is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA) -mediated IL-8 release with an IC50 value of 25.74 nM[3].

Product Specifications

CAS Number

[1622429-53-1]

Product Name Alternative

LXA4-d5

UNSPSC

12352211

Hazard Statement

H302-H315-H319-H335

Target

Endogenous Metabolite; Interleukin Related

Type

Isotope-Labeled Compounds

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

O[C@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](CCCC(O)=O)O)O)CCCC([2H])(C([2H])([2H])[2H])[2H]

Molecular Formula

C20H27D5O5

Molecular Weight

357.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Feng Hu, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF-κB pathways. J Dermatol Sci. 2015 Jun;78 (3) :181-8.|[3]Steven Bozinovski, et al. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012 Jan 17;109 (3) :935-40.|[4]Xinxin Liu, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.Sci Rep. 2017 Aug 2;7 (1) :7100.